Results 21 to 30 of about 13,346 (214)

Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors [PDF]

Scientific Reports
Lung cancer remains one of the most prevalent and lethal malignancies worldwide, with persistently poor 5-year survival rates across all stages. The development of novel therapies is therefore crucial for overcoming treatment resistance, improving ...
Nunghathai Sawasdee, Aussara Panya, Jatuporn Sujjitjoon, Pa-thai Yenchitsomanus, Chutamas Thepmalee   +4 more
doaj   +2 more sources

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human [PDF]

OncoImmunology
Despite advances in anti-disialoganglioside (GD2) immunotherapy, high-risk neuroblastoma (NB) remains a clinical challenge. Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity is a potent mechanism of action of anti-GD2 antibody ...
Mengjia Song, Yingxia Lan, Xiya Tan, Linnan Wu, Jia Zhu, Suying Lu, Feifei Sun, Min Gao, Junting Huang, Yi Que, Yu Zhang, Xiaona Fang, Mengzhen Li, Yumiao Mai, Juan Wang, Tong Xiang, Yizhuo Zhang   +16 more
doaj   +2 more sources

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. [PDF]

PLoS ONE, 2014
Anti-GD2 antibody is a proven therapy for GD2-positive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies.
Mickaël Terme, Mylène Dorvillius, Denis Cochonneau, Tanguy Chaumette, Wenhua Xiao, Mitchell B Diccianni, Jacques Barbet, Alice L Yu, François Paris, Linda S Sorkin, Stéphane Birklé   +10 more
doaj   +3 more sources

GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction

Translational Oncology, 2021
A novel disialoganglioside 2 (GD2)-specific chimeric antigen receptor (CAR)-modified T cell therapy against retinoblastoma (RB) were generated. GD2-CAR consists of a single-chain variable fragment (scFv) derived from a monoclonal antibody, hu3F8, that is
Jatuporn Sujjitjoon, Elias J Sayour, Mongkol Uiprasertkul   +2 more
exaly   +3 more sources

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies

Molecules, 2019
Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full ...
Irina V Kholodenko, Daniel V Kalinovsky, Elena V Svirshchevskaya   +2 more
exaly   +3 more sources

Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy [PDF]

FEBS Letters, 2013
Ganglioside GD2 is highly expressed on neuroectoderm‐derived tumors and sarcomas, including neuroblastoma, retinoblastoma, melanoma, small cell lung cancer, brain tumors, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma in children and adolescents, as well as liposarcoma, fibrosarcoma, leiomyosarcoma and other soft tissue sarcomas in adults.
Ahmed, Mahiuddin, Cheung, Nai-Kong V.
openaire   +3 more sources

Intermediary filament and GD2-expression in astrocytic tumors

, 2008
By means of immunhistochemical markers the expression of glial fibrillary acidic protein, vimentin and glykosphingolipid GD2 is investigated in 28 astrocytic tumors grading WHO II-IV. Statistically, there is found a high correlation in the cytoplasmatic expression of GFAP/GD2 as well as Vimentin/GD2 and GFAP/Vimentin.The semiquantitatively strongest ...
Lell, Barbara, Mennel, H.D. (Prof. Dr.)
core   +4 more sources

Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [PDF]

Jichu yixue yu linchuang, 2023
Objective To explore the feasibility of ganglioside GD2 as a marker for lung cancer stem cells (LCSCs). Methods Cancer stem cells (CSCs) of lung cancer cell lines were enriched by spheroid culturing in vitro; The expression of stemness-related genes ...
LI Zhen, DUAN Zhaojun, LUO Yunping
doaj   +1 more source

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas

Frontiers in Immunology, 2023
BackgroundDiffuse intrinsic pontine gliomas (DIPGs) are rare and fatal pediatric brainstem gliomas with no cure. Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells have been proven effective in treating glioblastoma (GBM) in preclinical
Pengcheng Zuo, Yaopeng Li, Chi He, Tantan Wang, Xu Zheng, Hao Liu, Zhen Wu, Junting Zhang, Xuebin Liao, Xuebin Liao, Liwei Zhang, Liwei Zhang   +11 more
doaj   +1 more source

Anti-GD2 Antibody Therapy for GD2-Expressing Tumors [PDF]

Current Cancer Drug Targets, 2010
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface of a variety of tumors for which no curative therapies exist for patients with advanced disease.
Fariba, Navid, Victor M, Santana, Raymond C, Barfield   +2 more
openaire   +2 more sources